Cardiovascular Imaging Startup Raywatt Raises USD 9.9M Series B, Targets 2028 Listing


Raywatt, a cardiovascular imaging diagnostics company, has closed a Series B round of USD 9.9 million (13 billion won), according to Sejong University. The company was founded by Professor Jinyong Ha of the university’s Department of AI Convergence Electronic Engineering as a faculty startup. The round brings Raywatt’s cumulative funding to more than USD 17.9 million (23.5 billion won).

article-image-15.jpg

Intervest, Life Asset Management, Yoo Kyung PSG Asset Management, Hyundai Technology Investment, L&S Venture Capital, Eugene Investment & Securities, Ecopro Partners and Kaicto Ventures were among the participants.

The investors cited Raywatt’s progress in commercializing its technology. The company, which makes imaging diagnostic devices for the heart and brain vasculature, has completed more than 100 clinical cases at Severance Cardiovascular Hospital. It has also won market approval in Vietnam, a tender at a United Arab Emirates government hospital, and designation as an innovative prototype by Korea’s Public Procurement Service.

Raywatt’s flagship product, FASTER OCT, is an optical coherence tomography (OCT) system. It rotates an intravascular catheter 400 times per second to deliver real-time, high-resolution cross-sectional images of the heart’s blood vessels at 400 frames per second. The company says this is among the fastest image acquisition speeds in the world. The system can also produce images with only saline rather than a conventional contrast agent, which reduces the risk of adverse reactions in patients.

FASTER OCT is in the final stage of review for U.S. Food and Drug Administration 510(k) clearance. Raywatt plans to use FDA clearance as a base for expanding in the global medical device market.

Raywatt also presented at TCT 2026, a major international cardiovascular intervention conference held recently in San Diego. It gave a technology presentation in the Innovation session for the third consecutive year. This year it took an additional order for FASTER OCT equipment and discussed cooperation with global medical device companies.

Raywatt plans to put the new capital toward building a global supply system after FDA clearance, developing next-generation products and upgrading its mass-production setup. It intends to accelerate overseas expansion and pursue a KOSDAQ technology-special listing in 2028.

Raywatt was founded in 2019 to commercialize the cardiovascular optical imaging technology that Professor Ha developed in his Sejong University laboratory. In its early days it relied on the university’s faculty startup support program and research infrastructure for technology development and commercialization, and it continues to work with the university through industry-academic cooperation. Sejong said the funding shows how a core technology from a university lab can progress to medical device commercialization and overseas expansion.

“This investment reflects investors’ recognition of our results in clinical work, regulatory approval and overseas expansion,” said Ha, Raywatt’s CEO. “With FDA clearance as a turning point, we will move into overseas supply in earnest and speed up development of next-generation products such as a cerebrovascular OCT. Through a KOSDAQ technology-special listing in 2028, we aim to become a world-class cardiovascular and cerebrovascular imaging device company.”

Share

Leave a Reply

Your email address will not be published. Required fields are marked *